Cargando…
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (...
Autores principales: | Robak, Tadeusz, Korycka, Anna, Lech-Maranda, Ewa, Robak, Pawel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253893/ https://www.ncbi.nlm.nih.gov/pubmed/19325518 http://dx.doi.org/10.3390/molecules14031183 |
Ejemplares similares
-
Toll-like receptors and their role in carcinogenesis and anti-tumor treatment
por: Wolska, Anna, et al.
Publicado: (2008) -
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022) -
Atypical Chronic Lymphocytic Leukemia—The Current Status
por: Robak, Tadeusz, et al.
Publicado: (2023) -
Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023) -
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)